


Zydus introduces biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care

19 February 2026 | News

ANYRA™ is India's first indigenously developed Aflibercept 2 mg biosimilar



Ahmedabad-based Zydus Lifesciences, has announced the launch of Anyra™, India's first indigenously developed biosimilar of Aflibercept 2 mg. Zydus has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer.

Anyra™ is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due

to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV).

With this launch, Zydus reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.

Presently, more than 100 million people in India are living with diabetes, making it one of the largest diabetic populations globally. Diabetic Retinopathy (DR) affects an estimated 7–8 million individuals, with many progressing to vision-threatening stages such as DME. Wet AMD impacts approximately 1.5–2 million elderly patients, while Retinal Vein Occlusions affect over 2 million individuals.

Speaking on the launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences said, “At Zydus, we are committed to making advanced biologics accessible to patients who need them most. ANYRA™ is a transformative step for affordable retinal care in India. By delivering a high-quality, indigenously developed Aflibercept 2 mg, we are expanding patient access to critical therapies with advanced biologics. Our focus remains on enabling patient-centric outcomes by leveraging science, health and innovation.”

Zydus has India's largest biosimilar portfolio with more than 13 biosimilars and complex biologic molecules developed and manufactured entirely in India. The company has established end-to-end capabilities across biologics development - from cell line research and process engineering to clinical trials, manufacturing, and regulatory approvals.